Skip to main content

Web Exclusives

Ovarian Cancer

Telehealth Coverage Expanded During the COVID-19 Pandemic

Ovarian Cancer

Trabectedin Added to Pegylated Doxorubicin May Be Viable Treatment for Recurrent Ovarian Cancer But Platinum Remains Standard of Care

Ovarian Cancer

NORA Clinical Trial Confirms Efficacy of Individualized Niraparib Starting Dose to Treat Platinum-Sensitive Ovarian Cancer

Ovarian Cancer

Increased Uptake of Neoadjuvant Chemotherapy Does Not Explain Trend Toward Improved Survival in Advanced Ovarian Cancer

Ovarian Cancer

Platinum-Based Chemotherapy Following Progression on PARP Inhibitor Maintenance Yields Greatest Benefit in Advanced Ovarian Cancer with Platinum-Free Interval >12 Months

FDA Updates

Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

Meeting Highlights

ESMO Highlights

Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer

Ovarian Cancer

ASCO Guidelines Support PARP Inhibitor Use in Maintenance and Recurrent Setting of Advanced Ovarian Cancer

Ovarian Cancer

Niraparib Efficacy in Advanced Ovarian Cancer Extends to All Biomarker Subgroups

Ovarian Cancer

Olaparib/Bevacizumab as First-Line Maintenance Reduces Risk for Progression or Death in Patients with Advanced Ovarian Cancer

Page 10 of 43
Results 91 - 100 of 430